Molecular Basis of Pediatric Liver Cancer
NCT03959800 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1600
Last updated 2025-09-12
Summary
The purpose of this retrospective and prospective project is to understand the molecular and genetic basis of liver cancer of childhood. Understanding the molecular and genetic bases of liver cancers can offer a better classification based on tumor biology, mechanisms and predisposition.
Conditions
- Childhood Liver Cancer
- Liver Malignant Tumors
- Embryonal Sarcoma of Liver (Disorder)
- Hepatoblastoma
- Hepatocellular Carcinoma
- Rhabdoid Tumor of Liver
Sponsors & Collaborators
-
University of Pittsburgh
lead OTHER
Eligibility
- Min Age
- 0 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-06-22
- Primary Completion
- 2028-06-30
- Completion
- 2029-06-30
Countries
- United States
Study Locations
More Related Trials
-
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
NCT07303712 ·Status: RECRUITING
-
Study of GNS561 in Patients With Liver Cancer
NCT03316222 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Prospective Liver Study
NCT01539993 ·Status: COMPLETED
-
A Prospective Multicenter Clinical Study of SCCG Protocol and ctDNA 5hmc in Predicting the Chemotherapy Sensitivity and Monitoring the Recurrence and Metastasis of Hepatoblastoma in Children and Adolescents
NCT07300449 ·Status: RECRUITING ·Phase: PHASE2
-
Multi-center Study on Therapy-oriented Molecular Subtyping of Hepatocellular Carcinoma
NCT03668158 ·Status: UNKNOWN
-
Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma
NCT03267641 ·Status: COMPLETED
-
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
NCT04145141 ·Status: ACTIVE_NOT_RECRUITING
-
Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
NCT05759858 ·Status: RECRUITING
-
A Study of Chromosomal Abnormalities as a Predictor of Staging and Prognosis in Patients With Liver Cancer
NCT05371873 ·Status: UNKNOWN
-
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
NCT01356628 ·Status: COMPLETED ·Phase: PHASE2
-
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma
NCT05516628 ·Status: RECRUITING ·Phase: PHASE2
-
Bevacizumab and Erlotinib in Inoperable and Metastatic Hepatocellular Carcinoma
NCT00287222 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
NCT02513199 ·Status: COMPLETED ·Phase: PHASE2
-
Precise Treatment in Hepatobiliary Cancers (PTHBC)
NCT02715089 ·Status: UNKNOWN
-
Protein Biomarker in Hepatocellular Carcinoma
NCT00465842 ·Status: TERMINATED
-
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
NCT03035006 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
NCT03144661 ·Status: TERMINATED ·Phase: PHASE1
-
Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience
NCT02557750 ·Status: UNKNOWN
-
PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC
NCT04273100 ·Status: UNKNOWN ·Phase: PHASE2
-
The Utility of Cell-free DNA Methylation Markers for Hepatocellular Carcinoma
NCT05573217 ·Status: UNKNOWN
-
Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy
NCT02066974 ·Status: UNKNOWN
-
Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
NCT01335074 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
NCT00250796 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study
NCT06096896 ·Status: ACTIVE_NOT_RECRUITING
-
Lenvatinib Combined With TACE to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma
NCT03838796 ·Status: UNKNOWN ·Phase: NA